Assessment of Activities of Daily Living in Dementia: Development of the Bristol Activities of Daily Living Scale

Bucks, Romola S.; Ashworth, Deborah L.; Wilcock, Gordon; Siegfried, Klaudius

doi:10.1093/ageing/25.2.113

Cited by 511 publications

(370 citation statements)

References 24 publications

Supporting

Mentioning

349

Contrasting

Unclassified

Order By: Relevance

“…Inter item and test-retest reliability were reported to exceed the standard criterion. Carers completed the Zarit Burden Interview (ZBI) (Zarit, Reever, & Bach-Peterson, 1980 ) and the Bristol Activities of Daily Living scale (BADLS) (Bucks, Ashworth, Wilcock, & Siegfred, 1996 ). The ZBI is a 22-item, 5-point Likert scale to assess the severity of carer perceptions of burden or stress in caring for a PWD.…”

Section: Methodsmentioning

confidence: 99%

Viewing and making art together: a multi-session art-gallery-based intervention for people with dementia and their carers

Camic

Tischler

Pearman

2013

Aging & Mental Health

175

305

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Viewing and making art together: a multi-session art-gallery-based intervention for people with dementia and their carers

Camic

Tischler

Pearman

2013

Aging & Mental Health

175

305

View full text Add to dashboard Cite

“…295 Face validity is determined by carer agreement regarding important items. BADL has good content and construct validity, but there are different views regarding test-retest reliability.…”

Section: Bristol Activities Of Daily Living Scalementioning

confidence: 99%

Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations

Webster

Groskreutz

Grinbergs-Saull

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

Background: There is currently no disease-modifying treatment available to halt or delay the progression of the disease pathology in dementia. An agreed core set of the best-available and most appropriate outcomes for disease modification would facilitate the design of trials and ensure consistency across disease modification trials, as well as making results comparable and meta-analysable in future trials. Objectives: To agree a set of core outcomes for disease modification trials for mild to moderate dementia with the UK dementia research community and patient and public involvement (PPI). Data sources: We included disease modification trials with quantitative outcomes of efficacy from (1) references from related systematic reviews in workstream 1; (2) searches of the Cochrane Dementia and Cognitive Improvement Group study register, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature, EMBASE, Latin American and Caribbean Health Sciences Literature and PsycINFO on 11 December 2015, and clinical trial registries [International Standard Randomised Controlled Trial Number (ISRCTN) and clinicaltrials.gov] on 22 and 29 January 2016; and (3) hand-searches of reference lists of relevant systematic reviews from database searches. Review methods: The project consisted of four workstreams. (1) We obtained related core outcome sets and work from co-applicants. (2) We systematically reviewed published and ongoing disease modification trials to identify the outcomes used in different domains. We extracted outcomes used in each trial, recording how many used each outcome and with how many participants. We divided outcomes into the domains measured and searched for validation data. (3) We consulted with PPI participants about recommended outcomes. (4) We presented all the synthesised information at a conference attended by the wider body of National Institute for Health Research (NIHR) dementia researchers to reach consensus on a core set of outcomes. Results: We included 149 papers from the 22,918 papers screened, referring to 125 individual trials. Eighty-one outcomes were used across trials, including 72 scales [31 cognitive, 12 activities of daily living (ADLs), 10 global, 16 neuropsychiatric and three quality of life] and nine biological techniques. We consulted with 18 people for PPI. The conference decided that only cognition and biological markers are core measures of disease modification. Cognition should be measured by the Mini Mental State Examination (MMSE) or the Alzheimer’s Disease Assessment Scale – Cognitive subscale (ADAS-Cog), and brain changes through structural magnetic resonance imaging (MRI) in a subset of participants. All other domains are important but not core. We recommend using the Neuropsychiatric Inventory for neuropsychiatric symptoms: the Disability Assessment for Dementia for ADLs, the Dementia Quality of Life Measure for quality of life and the Clinical Dementia Rating scale to measure dementia globally. Limitations: Most of the trials inclu...

show abstract

“…MCI subjects exhibited moderate to severe deficits in episodic memory, typically O1.5 SD below the mean of age-matched normative scores on episodic memory tests without notable impairments on other neuropsychological tests. MCI subjects were not impaired in activities of daily living as determined by the assessments of Bristol Activities of Daily Living Scale (Bucks et al, 1996), Functional Activities Questionnaire (Pfeffer et al, 1982), Blessed-Roth Dementia Scale (Blessed et al, 1968), and Dementia Rating Severity Scale (Clark and Ewbank, 1996). Eight MCI subjects were taking cholinesterase inhibitor, such as donepezil hydrochloride, at the time of evoked potential testing.…”

Section: Subjectsmentioning

confidence: 99%

Auditory brain-stem, middle- and long-latency evoked potentials in mild cognitive impairment

Irimajiri

Golob

Starr

2005

Clinical Neurophysiology

View full text Add to dashboard Cite

Objective: Mild cognitive impairment (MCI) is a selective episodic memory deficit in the elderly with a high risk of Alzheimer's disease. The amplitudes of a long-latency auditory evoked potential (P50) are larger in MCI compared to age-matched controls. We tested whether increased P50 amplitudes in MCI were accompanied by changes of middle-latency potentials occurring around 50 ms and/or auditory brainstem potentials. Methods: Auditory evoked potentials were recorded from age-matched controls (nZ16) and MCI (nZ17) in a passive listening paradigm at two stimulus presentation rates (2/s, 1/1.5 s). A subset of subjects also received stimuli at a rate of 1/3 s. Results: Relative to controls, MCI subjects had larger long-latency P50 amplitudes at all stimulus rates. Significant group differences in N100 amplitude were dependent on stimulus rate. Amplitudes of the middle-latency components (Pa, Nb, P1 peaking at approximately 30, 40, and 50 ms, respectively) did not differ between groups, but a slow wave between 30 and 49 ms on which the middle-latency components arose was significantly increased in MCI. ABR Wave V latency and amplitude did not differ significantly between groups. Conclusions: The increase of long-latency P50 amplitudes in MCI reflects changes of a middle-latency slow wave, but not of transient middle-latency components. There was no evidence of group difference at the brain-stem level. Significance: Increased slow wave occurring as early as 50 ms may reflect neurophysiological consequences of neuropathology in MCI.

show abstract

Assessment of Activities of Daily Living in Dementia: Development of the Bristol Activities of Daily Living Scale

Cited by 511 publications

References 24 publications

Viewing and making art together: a multi-session art-gallery-based intervention for people with dementia and their carers

Viewing and making art together: a multi-session art-gallery-based intervention for people with dementia and their carers

Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations

Auditory brain-stem, middle- and long-latency evoked potentials in mild cognitive impairment

Contact Info

Product

Resources

About